Newly identified process keeps some immune cells on their toes – News-Medical.Net

Cancer cells use an unusual mechanism to migrate into new tissue and form metastases there. The same process probably also keeps some immune cells on their toes. This is the result of a recent study led by the University of Bonn. According to the study, certain structures, the centrioles, increase in number. This makes it easier for them to maintain their direction and thus migrate more quickly to the lymph nodes, where they activate other immune cells. The results have now been published in the Journal of Cell Biology.

Like the police, the immune system relies on division of labor. First of all, there are the dendritic cells. They search the tissue around the clock for traces of suspicious intruders, called antigens. If they are successful, they rush to the lymphatic vessels and from there to the draining lymph nodes. There they present their findings to a powerful search team, the T cells. These endogenous troops now know which enemy to fight.

This attack must take place before the invaders cause major damage or multiply too much. It is therefore important that dendritic cells migrate as quickly as possible to the briefing in the lymph node.

We have discovered a mechanism that helps them doing this. To do so, they form more of certain structures called centrosomes. These help them maintain their direction for longer and thus reach the lymphatic vessels more quickly."

Prof. Dr. Eva Kiermaier, LIMES Institute (Life and Medical Sciences), University of Bonn

Centrosomes belong to the organelles - these are molecular complexes that are responsible for specific tasks in cells, much like the organs in the body. Normally, there is exactly one centrosome in each human cell. Shortly before cell division, it doubles. The two copies migrate to opposite poles of the cell and stretch a bundle of fibers between them, the microtubules. With them, they pull the chromosomes (which have also doubled) apart during division. Each of the resulting daughter cells thus receives a complete set of genetic material as well as one of the two centrosomes.

"However, centrosomes are also responsible for organizing the cytoskeleton during cell migration," emphasizes Kiermaier, who was brought to the Rhine from Lower Austria (IST Austria, Klosterneuburg) in 2017 through the returnee program of the state of North Rhine-Westphalia. "By this we mean fiber-like structural proteins that give the cell its shape and provide it with stability." The cytoskeleton also decides where "front" and "back" are in a cell. And that, in turn, affects its direction of movement. "We have now been able to show that dendritic cells form multiple centrosomes as soon as they come into contact with an antigen," says Ann-Kathrin Weier. The PhD student at the LIMES Institute shares first authorship of the publication with her colleague Mirka Homrich. Both performed important parts of the experiments.

Dendritic cells have a problem: they do not know where the next lymphatic vessel is via which they can reach the lymph node. In their search, they proceed according to the strategy of "trial and error": they run in one direction for a short while and then change it if they have not encountered a vessel in the process. "The more centrosomes they have, the longer they stay on course before continuing to search in a different direction," says Mirka Homrich. "We were able to show in computer simulations that this allows them to find the lymphatic vessels much faster than they normally would." In the process, the proliferation of centrosomes adjusts their staying power just right - so they don't stick too stubbornly to their direction. This would increase the risk of them going astray and getting completely lost.

The mechanism identified in the study was previously completely unknown in healthy cells. Cancer cells were assumed to use it to form metastases. However, the multiplied centrosomes must not be freely distributed inside the cells. Otherwise, they would severely disrupt functions such as cell division. In both tumor and dendritic cells, the organelles therefore congregate at a single site - they cluster. "There are now agents that disrupt this clustering of centrosomes," says Kiermaier, who is also a member of the ImmunoSensation2 Cluster of Excellence and the Transdisciplinary Research Area "Life and Health" at the University of Bonn. "As a result, the cancer cells can no longer divide correctly, but die."

However, it is also possible that these substances interfere with the immune system - after all, the centrosomes cluster there as well. "We've tested several of these agents in cell cultures," she says. "We've actually found evidence that they could significantly impair the effectiveness of the immune defense." If that will be confirmed in clinical trials, it would be bad news as there could be considerable side effects if the active substances were used in cancer therapy.

In addition to the University of Bonn, the Charles University in Vestec, Czech Republic, and the Institutes of Science and Technology in Austria and Spain were involved in the work.

Source:

Journal reference:

Weier, A-K., et al. (2022) Multiple centrosomes enhance migration and immune cell effector functions of mature dendritic cells. Journal of Cell Biology. doi.org/10.1083/jcb.202107134.

Read the rest here:
Newly identified process keeps some immune cells on their toes - News-Medical.Net

What does biochemistry have to do with climate change? – ASBMB Today

Ask Karla Neugebauer about her journey to climate activism, and she highlights two moments.

The first was in 2006. She was on vacation in Australias Northern Territory with her family, camping in the outback not far from Alice Springs. That part of Australia, known to some as the Red Centre, is beautiful, severe desert country the kind of place where its unwise to start a road trip without a five-gallon water tank and a spare tire. The rocks are russet. In the deep shade of narrow gullies in the MacDonnell mountain range, small pools of water cool the air around them, making small miracles of oasis.

Yale University

Karla Neugebauer's interest in climate change was inspired by a driving tripin the Australian outback and a dinner conversation with her son.

Neugebauer read aloud on the road trip, as she often did when her children were young. She came to an article by paleontologist turned climate writer and activist Tim Flannery outlining the fiery future Australia faced if it maintained its inaction on climate change.

Being immersed in the natural environment and then reading this thing was just kind of devastating, Neugebauer said. I remember sitting in the back seat and just bawling.

At the time, she was a group leader at the Max Planck Institute of Molecular Cell Biology and Genetics in Germany. There was no clear link between her professional expertise, which concerns RNA splicing and gene expression, and the looming crisis.

More than decade later, she sat down to dinner with her son and a friend he had grown up with. The world had continued to careen down the path of escalating emissions and rising global temperatures Flannery had described. Neugebauer had moved to the U.S. by this time and had taken a faculty position at Yale, but her son, a young adult, had returned to Dresden for an internship. He and his friend had become involved in the Fridays for Future climate protests; sometimes, their friends had been arrested. If they did choose to go to college, both young men said, the only fields worth studying would be environmental engineering or politics disciplines that could save the planet.

Their deep concern for the future galvanized her to act and made her wonder why other areas of expertise did not also seem like productive tools for climate activists. It disappointed me that other disciplines didnt come to their minds, Neugebauer said.

The more closely she looked at biochemistry, the less she could blame young people for overlooking its relevance. When she canvassed other universities for ideas about how to teach the biology of climate science, she came up emptyhanded. At interdepartmental meetings she began to attend virtually a few years later, during the pandemic, she was the only biochemist in attendance.

Neugebauer argues that the field has become myopically focused on human health because of funding organized around diseases of individual organs. Even basic researchers must think and write in terms of curing disease to secure grants.

I submit to you the work Im doing on stress in HeLa cells is relevant to climate change because Im studying how gene expression changes to parameters that are going to change for the algae and the fish, Neugebauer said. Yet when she talks to her neighbors about her work, she hears herself describing applications in cancer. Im not curing cancer! Im a basic scientist. Im asking fundamental questions that I believe are terribly important for allof these reasons.

She illustrated that belief by launching an unconventional seminar in the fall of 2021. The course, called Biochemistry and our Changing Climate, explores the basic biochemistry that governs living systems response to a changing world.

Neugebauer guides her students through discussions of articles that illuminate the core concepts of biochemistry in a climate context. She talks about the aromatic amino acid synthesis pathways that the pesticide Roundup inhibits and about how cell biological responses to heat stress contribute to coral bleaching. She talks about nitrogen fixation a biochemical process that her departments core courses do not cover. She talks about engineering enzymes that could recycle plastics or entomb atmospheric carbon in building materials.

Karla Neugebauer

In her course, Karla Neugebauer encourages students to propose research projects that would answer open questions about the links between biochemistry and climate change such as why red algae reduces cows methane emissions.

People have a hard time understanding what I mean by a class about biochemistry and climate change, she said. The course isnt focused on ecology or on bioengineering. Instead, she seeks to explore on a molecular level the mechanisms by which climate change is affecting and will alter further the living world. It frustrates her when students ask questions that biochemistry clearly could answer for example, What molecule from red algae reduces cows methane emissions? but has not.

She aims to show her students that biochemists have a role to play in understanding climate change and a role to play in adapting to and mitigating the crisis.

Neugebauer has spent time recently visiting other departments to tell them about her course. By the time you receive this magazine, she will be immersed in teaching it for a second time. Im on a mission to make people aware of this, she said.

Karla Neugebauer and Henry Jakubowski (author of the climate change article How to be a climate activist) will host an interest group on Biochemistry and Climate Change on March 25 at Discover BMB 2023, the ASBMB annual meeting in Seattle.

Originally posted here:
What does biochemistry have to do with climate change? - ASBMB Today

Biology Alumna Named Conn.’s Teacher of the Year – Susquehanna University

October 13, 2022

What keeps Carolyn Kuhr 98 Kielma coming back to teaching year after year is not the biology content she teaches, but the connections she shares with her students.

Kielma was named Connecticuts Teacher of the Year by Gov. Ned Lamont and the Connecticut State Department of Education. She teaches biology and biotechnology and forensics at Bristol Eastern High School.

I am elated and honored to represent my students and my city, Kielma said. The longer the dust settles, the more overwhelmed with gratitude I am. So many former students, colleagues and parents are reaching out to congratulate me and wish me luck. I had no idea how much I was able to impact my community.

Growing up, Kielma said she was a curious child with an early passion for learning. Upon graduating from Susquehanna University, she worked several concurrent jobs while saving up to continue her education at graduate school which she did, graduating in 2002 with a Master of Education from the University of New Haven.

After my first few years in the profession, I discovered that learning science is not truly the goal for my students, Kielma said. I now believe teaching is not only about the content but about helping youth become better humans. I strive to be the type of teacher that I needed in my adolescent years the trusted adult that students can come to when they need help, whether inside or outside the classroom.

Now 20 years into her career, Kielma said she still gets excited when chatting with her current students about the research opportunities they could have if they find mentors like the ones she had at Susquehanna, including Jack Holt, professor of biology; Peggy Peeler, Charles B. Degenstein professor of biology; Tom Peeler, associate professor emeritus of biology; and David Richard, presidential professor of biology.

I will never forget being able to keep frog hearts beating in culture on a petri dish during cell biology lab and trudging through the waters collecting samples from the Susquehanna River during limnology, she said. They supported me by believing in me, even when I didnt. Thats one of the most important gifts I can give my current students too.

Kielma also believes in students shes never met those at Susquehanna who are just on the precipice of beginning their own careers in teaching.

I think the greatest advice I can offer is to be patient with yourself honing a craft like education takes time. Lean into the educators in your building; within your school will be a group of highly educated, motivated and courageous professionals who understand the power of lifelong learning. Trust in them and trust in yourself, Kielma said. Remember to stay positive and do not get caught up in negativity because you are making a difference, even if it is with one student at a time.

Read the original post:
Biology Alumna Named Conn.'s Teacher of the Year - Susquehanna University

Cell Isolation Global Market Report 2022: Increasing Emphasis on Cell-Based Research Bolstering Growth – PR Newswire

DUBLIN, Oct. 18, 2022 /PRNewswire/ --The "Cell Isolation Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027" report has been added to ResearchAndMarkets.com's offering.

The global cell isolation market size reached US$ 10.3 Billion in 2021. Looking forward, the publisher expects the market to reach US$ 24.6 Billion by 2027, exhibiting a CAGR of 15.62% during 2021-2027. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor.

Cell isolation, or separation, refers to the process of identifying and removing one or more specific cells from a heterogeneous mixture of cell population. The targeted cells are identified, isolated and separated according to their type. Some commonly used methods for cell isolation include magnet-activated cell separation, filtration, centrifugation and flow cytometry.

Cell isolation is also used to diagnose diseases, cellular research and therapies by analyzing the ribonucleic acid (RNA) expressions. It aids in minimizing experimental complexity while analyzing the cells and reducing the interference from other cell types within the sample. As a result, it finds extensive application in cancer research, stem cell biology, immunology and neurology.

Cell Isolation Market Trends:

Significant growth in the medical and pharmaceutical industries is one of the key factors creating a positive outlook for the market. Furthermore, increasing emphasis on cell-based research is providing a thrust to the market growth. Researchers actively utilize isolated cells to develop novel cell therapies and cell-based treatments for various chronic medical ailments. Pharmaceutical manufacturers are also widely using cell isolation technologies to improve drug discovery and develop drugs with enhanced efficacies. In line with this, the increasing requirement for personalized medicines is also contributing to the growth of the market.

Additionally, the development of advanced separation tools for proteins, nucleic acids, chromatin and other complex cells for subsequent analysis is also contributing to the growth of the market. Other factors, including extensive research and development (R&D) activities in the field of biotechnology, along with the implementation of favorable government policies, are anticipated to drive the market toward growth.

Key Market Segmentation

Breakup by Technique:

Breakup by Cell Type:

Breakup by Product:

Breakup by Application:

Breakup by End Use:

Breakup by Region:

Key Questions Answered in This Report:

Key Topics Covered:

1 Preface

2 Scope and Methodology

3 Executive Summary

4 Introduction

5 Global Cell Isolation Market

6 Market Breakup by Technique

7 Market Breakup by Cell Type

8 Market Breakup by Product

9 Market Breakup by Application

10 Market Breakup by End Use

11 Market Breakup by Region

12 SWOT Analysis

13 Value Chain Analysis

14 Porters Five Forces Analysis

15 Price Analysis

16 Competitive Landscape

Companies Mentioned

For more information about this report visit https://www.researchandmarkets.com/r/a39mjl

Media Contact:

Research and MarketsLaura Wood, Senior Manager[emailprotected]

For E.S.T Office Hours Call +1-917-300-0470For U.S./CAN Toll Free Call +1-800-526-8630For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907Fax (outside U.S.): +353-1-481-1716

Logo: https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg

SOURCE Research and Markets

Read the original:
Cell Isolation Global Market Report 2022: Increasing Emphasis on Cell-Based Research Bolstering Growth - PR Newswire

Replay establishes distinguished Scientific Advisory Board of genomic medicine and cell therapy … – The Bakersfield Californian

Replay establishes distinguished Scientific Advisory Board of genomic medicine and cell therapy experts

San Diego, California and London, UK, October 17, 2022 Replay, a genome writing company reprogramming biology by writing and delivering big DNA, today announced that it has established a scientific advisory board (SAB) comprising ten experts across a broad range of areas of scientific importance in genomic medicine and cell therapy.

The newly formed SAB will provide input into Replays strategy, portfolio of next-generation genomic and cell therapy medicines, and associated technology platforms. The SAB complements Replays industry seasoned management team and board.

Adrian Woolfson, Executive Chairman, President and Co-founder of Replay, commented: The multi-disciplinary nature of our scientific advisory board reflects Replays commitment to invoking innovation from a broad range of scientific specialties and leveraging this across our research and development programs. Our new advisors represent some of the best scientific minds of their generation and bring a unique and differentiated portfolio of expertise into the Company. Their contribution to Replay will be invaluable as we continue to address some of the most significant challenges in genomic medicine and cell therapy.

Lachlan MacKinnon, Chief Executive Officer and Co-founder of Replay, added: Following on from our recent launch, the formation of our uniquely distinguished scientific advisory board further demonstrates Replays commitment to developing a cutting-edge portfolio of medicines guided by world-class science. The combined inter-disciplinary expertise of our scientific advisory board brings tremendous knowledge and experience into the Company as we continue to expand our operations, with a view to developing transformative genomic medicines.

Replays SAB will be chaired by Professor Roger Kornberg, PhD, a biochemist whose laboratory work has focused on the molecular basis of eukaryotic transcription and in particular the structure of RNA polymerase and the nucleosome.

Professor Roger Kornberg, PhD, Chairman of Replays Scientific Advisory Board, said: Replays scientific advisory board incorporates expertise across several areas relevant to Replays genomic medicine and cell therapy technology platforms. I am excited to be working with this exceptional group of scientists and believe we can make a compelling contribution and help Replay realize its vision for genomic medicine.

Replays SAB members are as follows:

Professor Roger D. Kornberg PhD (Chairman), is the Winzer Professor of Medicine in the Department of Structural Biology at Stanford University School of Medicine. He was awarded the Nobel Prize in Chemistry (2006).

Professor Carl H. June, MD, is the Richard W. Vague Professor in Immunotherapy in the Department of Pathology and Laboratory Medicine at the Perelman School of Medicine at the University of Pennsylvania. He is Director of the Parker Institute for Cancer Immunotherapy at the University of Pennsylvania, Director of the Center for Cellular Immunotherapies at the Perelman School of Medicine, and Director of Translational Research at the Abramson Cancer Center. He was the co-founder of TMunity.

Professor Robert S. Langer, ScD, FREng,is one of 12 Institute Professors at the Massachusetts Institute of Technology (MIT), co-founder of Moderna, and was formerly Chair of the FDAs Science Board. He has been awarded 40 honorary doctorates, written over 1,500 articles, and received over 220 awards.

Professor Lynne E. Maquat, PhD, is the J. Lowell Orbinson Endowed Chair and Professor of Biochemistry and Biophysics, University of Rochester Medical Center, and founding Director of the Center for RNA Biology, University of Rochester, Rochester NY. She was awarded the Wolf Prize in Medicine from Israel (2021) and the Warren Alpert Foundation Prize from Harvard Medical School (2021).

Professor Dame Carol Robinson, DBE FRS FMedSci FRSC, is the Dr Lees Professor of Physical and Theoretical Chemistry, the Founding Director of the Kavli Institute for Nanoscience Discovery at Oxford, and a Founder of OMass Therapeutics. She is a Professorial Fellow at Exeter College, Oxford, and was formerly President of the Royal Society of Chemistry.

Professor David V. Schaffer, PhD, is the Hubbard Howe Professor of Chemical and Biomolecular Engineering, Bioengineering, and Neuroscience at the University of California, Berkeley, where he is Director of theBakar BioEnginuity Hub and Director of the California Institute for Quantitative Biosciences (QB3). He was the co-founder of 4D Molecular Therapeutics, Ignite Immunotherapies, Rewrite, and 5 additional companies.

Professor Stuart L. Schreiber, PhD, is the Morris Loeb Professor of Chemistry and Chemical Biology at Harvard University. He is a co-founder of the Broad Institute at Harvard University and MIT and co-founder of Harvards Institute of Chemistry and Cell Biology. He was awarded the Wolf Prize in Chemistry (2016).

Professor Pamela Silver, PhD, is the Elliot T. and Onie H. Adams Professor of Biochemistry and Systems Biology in the Department of Systems Biology at Harvard Medical School, and a founding member of the Wyss Institute for Biologically Inspired Engineering at Harvard Medical School.

Professor Sir John E. Walker, FRS FMedSci, is Emeritus Director and Professor at the MRC Mitochondrial Biology Unit at the University of Cambridge, England, and a fellow of Sidney Sussex College, Cambridge. He was awarded the Nobel Prize in Chemistry (1997).

Professor John Fraser Wright, PhD, is Professor of Pediatrics, Division of Hematology, Oncology, Stem Cell Transplantation and Regenerative Medicine, and Director of Technology Innovation at the Center for Definitive and Curative Medicine at Stanford University. He is co-founder and was Chief Technology Officer at Spark Therapeutics and is co-founder and Chief Scientific Advisor at Kriya Therapeutics.

Ends

About Replay

Replay is a genome writing company, which aims to define the future of genomic medicine through reprogramming biology by writing and delivering big DNA. The Company has assembled a toolkit of disruptive platform technologies including a high payload capacity HSV platform, a hypoimmunogenic cell therapy platform, and a genome writing platform to address the scientific challenges currently limiting clinical progress and preventing genomic medicine from realizing its full potential. The Companys hub-and-spoke business model separates technology development within Replay from therapeutic development in product companies that leverage its technology platforms. For example, Replays synHSV technology, a high payload capacity HSV vector capable of delivering up to 30 times the payload of AAV, is utilized by Replays four gene therapy product companies, bringing big DNA treatments to diseases affecting the skin, eye, brain, and muscle. The Company has, additionally, established an enzyme writing product company that leverages its evolutionary inference machine learning and genome writing technology to optimize enzyme functionality. Replay is led by a world-class team of academics, entrepreneurs, and industry experts.

The Company raised $55 million in seed financing in July 2022 and is supported by an international syndicate of investors including: KKR, OMX Ventures, ARTIS Ventures, and Lansdowne Partners.

Replay is headquartered in San Diego, California, and London, UK. For further information please visit http://www.replay.bio and follow us on LinkedIn and Twitter.

Contacts:

Replay

Dr Adrian Woolfson/Lachlan MacKinnon

info@replay.bio

Consilium Strategic Communications Media relations

Amber Fennell/Tracy Cheung/Andrew Stern

replay@consilium-comms.com

See original here:
Replay establishes distinguished Scientific Advisory Board of genomic medicine and cell therapy ... - The Bakersfield Californian

Plants use their roots to measure manganese concentration available in the soil – EurekAlert

image:Arabidopsis seedlings have been exposed to manganese deficiency, and cytosolic calcium dynamics have been visualized utilizing the GCaMP6f-mCherry calcium biosensor. The calcium dynamics in roots are presented as false color images for selected timepoints after onset of manganese deficiency (from left). view more

Credit: University of Mnster - Kudla Group

Every living organism needs the element manganese as an essential nutrient. In plants, for example, it plays a major role in breaking down water into oxygen and hydrogen during photosynthesis. A team of German and Chinese researchers are the first to demonstrate, using the model species thale cress (Arabidopsis thaliana), how plants sense manganese deficiency and which processes then take place in the plant at the molecular level. The researchers showed that a hitherto undetected group of cells in the plant root plays a decisive role. The researchers hope that the results of their work will in the future lead to methods for making plants more resistant to manganese deficiency a condition which often occurs in alkaline and calcareous soils.

Prof. Jrg Kudla from the Institute of Plant Biology and Biotechnology at the University of Mnster (Germany) is one of the leading authors of the study and, as he says, There have been a lot of studies focusing on which proteins are involved in the uptake and transportation of manganese within a cell. But how the manganese balance is regulated at the level of the organism is completely unknown. Because calcium is involved as a messenger substance in numerous other regulating processes in the plant, the researchers asked themselves whether it also plays a role in regulating the manganese balance.

Manganese deficiency triggers oscillating calcium signals

The team identified a special cell group in the plant root and gave it the name manganese-sensitive niche. Unlike all other root cells, these cells display a special reaction in response to manganese deficiency: the calcium concentration within the cells rises and falls, several times in succession, as long as the deficiency lasts. Every oscillation lasts approximately 30 minutes. Nobody had previously observed such multi-cellular oscillations in the calcium concentration which are built up through the coordinated occurrence of calcium signals in individual cells in plants, says Kudla. Just a few hundred cells jointly build up the signal. The epidermal cells the cells in the outermost root layer are the first to begin increasing the calcium concentration. Then the cells situated further inside gradually follow suit before the whole process is then reversed.

Third stimulus-specific sensitive niche now discovered

In earlier work, researchers led by Jrg Kudla had already discovered two further sensitive niches in other areas in the root a potassium-sensitive niche and a sodium-sensitive niche. Here, too, the roots reacted by producing multicellular calcium signals in specific cell groups in response to changes in the ion concentrations in the environment. However, the researchers did not observe any oscillations unlike in the manganese-sensitive niche.

In their current study, the researchers discovered that the calcium oscillations triggered by manganese deficiency activate two special enzymes so-called Calcium-Dependent Protein Kinases (CPK21 and CPK23) and that these two enzymes, for their part, stimulate the uptake of manganese. As the kinase frees itself from the calcium, and these again become inactive. Our hypothesis is that every oscillation starts this process anew until the plant has achieved a sufficient uptake of manganese, says Kudla. The manganese transporter NRAMP1, which is responsible for transporting the manganese into the cells of the root, is part of the process. The protein kinases CPK21 and CPK23 interact with this transporter and regulate the uptake of manganese by phosphorylating one specifc amino-acid (Thr498).

In order to demonstrate the occurrence of the calcium signals, the researchers used high-resolution microscopy and, for the first time, ultra-sensitive molecular calcium-biosensors. Biosensors generally visualise changes in concentrations of bioactive substances such as calcium in cells and tissues. The team combined these studies, involving in vivo biosensor technology, with genetic, cell-biological and biochemical methods in order to clarify the underlying molecular mechanisms. In addition to the Mnster researchers, scientists from the College of Life Sciences, Northwest A&F University in Shaanxi and the Biotechnology Research Institute, Chinese Academy of Agricultural Sciences in Beijing (China) as well as from the Martin Luther University Halle-Wittenberg (Germany) were also involved.

Proceedings of the National Academy of Sciences

Experimental study

Not applicable

Ca-dependent phosphorylation of NRAMP1 by CPK21 and CPK23 facilitates manganese uptake and homeostasis in

30-Sep-2022

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.

Go here to see the original:
Plants use their roots to measure manganese concentration available in the soil - EurekAlert

Berkeley Lights to Report Third Quarter 2022 Financial Results on November 8, 2022 – Berkeley Lights (NAS – Benzinga

EMERYVILLE, Calif., Oct. 18, 2022 /PRNewswire/ --Berkeley Lights, Inc. BLI, a leader in digital cell biology, today announced that the Company will be reporting financial results for the third quarter 2022 after market on Tuesday, November 8, 2022. Company management will be webcasting a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

Live audio of the webcast will be available on the "Investors" section of the Company's website at http://www.berkeleylights.com. The webcast will be archived and available for replay after the event.

About Berkeley Lights

Berkeley Lights is a leading digital cell biology company focused on enabling and accelerating the rapid development and commercialization of biotherapeutics and other cell-based products for our customers. The Berkeley Lights Platform captures deep phenotypic, functional, and genotypic information for thousands of single cells in parallel and can also deliver the live biology customers desire in the form of the best cells. Our platform is a fully integrated, end-to-end solution, comprising proprietary consumables, including our OptoSelect chips and reagent kits, advanced automation systems, and application software. We developed the Berkeley Lights Platform to provide the most advanced environment for rapid functional characterization of single cells at scale, the goal of which is to establish an industry standard for our customers throughout their cell-based product value chain.

Forward-Looking Statements

To the extent that statements contained in this press release are not descriptions of historical facts regarding Berkeley Lights or its products, they are forward-looking statements reflecting the current beliefs and expectations of management. Such forward-looking statements involve substantial known and unknown risks and uncertainties that relate to future events, and actual results and product performance could differ significantly from those expressed or implied by the forward-looking statements. Berkeley Lights undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties relating to the Company's growth and continual evolution see the statements in the "Risk Factors" sections, and elsewhere, in our filings with the U.S. Securities and Exchange Commission.

SOURCE Berkeley Lights, Inc.

Continue reading here:
Berkeley Lights to Report Third Quarter 2022 Financial Results on November 8, 2022 - Berkeley Lights (NAS - Benzinga

Single Cell Genome Sequencing Market Will Radically Change Globally in Next Eigth Years | Illumina, Inc., Fludigim Corporation, Thermo Fisher…

Coherent Market Insightshas announced new analysis on Single Cell Genome Sequencing Market Status 2022-2028 which has been prepared based on an in-depth market analysis with inputs from industry experts and top vendors in the business. The report covers the market landscape and its development prospects over the coming years. The report also contains a discussion of the key vendors operating in this market.

The market analysis report speaks about thegrowth rate ofSingle Cell Genome Sequencing markettill2028 manufacturing process,key factorsdriving this market withsales, revenue, and price analysisof top manufacturers of Market,distributors, traders and dealersofSingle Cell Genome SequencingMarket.

Single cell genome sequencing involves isolating a single cell and amplifying and sequencing genes within that single cell. Sequencing single cell carries significant importance as individual cells can differ at great extent in size, protein levels, and expressed RNA transcripts. These variations could provide important insights about several research applications such as cancer research, stem cell biology, immunology, developmental biology, and neurology. Single-cell analysis enables a closer view of the gene expression of individual cells to understand their functions in complex tissues.

Kits and instruments based on technological platform such asNext Generation Sequencing (NGS), polymerase chain reaction (PCR), quantitative polymerase chain reaction (qPCR), and others provide high-throughput sequencing of individual cells. Single cell sequencing has significantly evolved with in-depth understanding of genomes and increasing genomic research to trace the root cause of many chronic diseases.

Sample Copy of Research Report @ https://www.coherentmarketinsights.com/insight/request-sample/2059

Single Cell Genome Sequencing Market study consists of market space, opportunities and threats faced by vendors in the Single Cell Genome Sequencing Industry, opportunities, industry risk, and market overview. The process is thoroughly investigated in three areas: suppliers of raw materials and equipment, various production-related expenses (material costs, labour costs, and so on), and the actual process.

Single Cell Genome Sequencing Market studies provide a thorough modest picture of the market position and company profiles of the major competitors operating in the global market. It also provides a summary of product specifications, production analysis, technology, and product type, while taking into account essential factors such as gross, gross margin, revenue, and cost structure. By providing a detailed image of this market, the study assists the user in strengthening their decisive capacity to plan strategic steps to begin or expand their company.

If you are or plan to be active in the Single Cell Genome Sequencing Market, this study will provide you with a comprehensive outlook. It is critical that you keep your industry information current and organised by major corporations. If you have a distinct set of players/manufacturers based on geography, or if you require regional or country split data, we can customise reports to meet your needs.

Major Players Are:Illumina, Inc., Fludigim Corporation, Thermo Fisher Scientific, F. Hoffmann-La Roche Ltd., Inc., QIAGEN, Bio-Rad Laboratories, 10x Genomics, Novogene, BGI, Oxford Nanopore Technologies, and Pacific Biosciences

Single Cell Genome Sequencing Market Dynamics

Single cell genome sequencing is one of most focused area of research for finding cure for chronic disease such as cancer as it could help to observe tumor microenvironment. According to World Health Organization (WHO), cancer is one of leading non-communicable disease and second leading cause of death, worldwide. According to a report by International Age for Research on Cancer (IARC) in 2012, around 14.1 million new cases of cancer were registered with around 8.8 million death and around 32.6 million people are living with cancer in the year 2012.

Introduction of new therapies for the treatment of cancer such as personalized medicine (Immuno-oncology and others.) is expected to increase the adaption ofsingle cellgenomic sequencing for advancing research in order to observe cellular level changes in cancer cells.

Furthermore, application of single cell genomic sequencing in other diseases such as immune system disorder and infectious diseases (Tuberculosis, meningococcal disease, and others.) is a key factor contributing to the market growth. According to statistics given by Centers for Disease Control and Prevention 2017 Vital Signs, around 54.4 million U.S. adults suffer from arthritis which is equivalent to 25% of the U.S. population. Rheumatoid arthritis which is leading autoimmune disorder holds significant share in the overall arthritis prevalence.

Continuous development in sequencing technologies is further expected to propel growth of the single cell genome sequencing market. PCR and next generation sequencing are rapidly emerging as preferred technology for several applications including single cell genomic sequencing. For instance, Oxford Nanopore, in 2017, launched two sequencing kits for direct or PCR cDNA analysis that facilitate easy use and provide results in reduced time and cost.

Several collaborations amongst commercial companies and academic and research institutes is expected to propel the single cell genome sequencing market growth. For instance, in 2015, three single cell genomics centers were started in Sweden, Australia and the U.Swith an objective to facilitate R&D activities in single cell genome sequencing. The center in Australia was started with collaboration of Monash University, the University of Melbourne, the University of Newcastle and the Hudson Institute of Medical Research, and Fluidigm Corporation.

Major Point cover in this Single Cell Genome Sequencing Market report are:

Request For Customization of Research Report @ https://www.coherentmarketinsights.com/insight/request-customization/2059

Key Points :

Companies are focused on new product launches and collaborations to extend their market share. For instance,

Detailed Segmentation:

On the basis of product type:

On the basis of technology:

On the basis of end users:

Reasons to buy this Single Cell Genome Sequencing Market Report

The following section also discusses the supply-demand gap. Aside from the previously mentioned information, the growth rate of the Single Cell Genome Sequencing market in 2028 is also explained. Additionally, consumption tables and figures for the Single Cell Genome Sequencing market are provided by type and application.

Points cover in Single Cell Genome Sequencing Market Research Report:

Chapter 1: Overview of Single Cell Genome Sequencing Market (2022-2028)

Definition Specifications Classification Applications Regions

Chapter 2: Market Competition by Players/Suppliers 2022 and 2028

Manufacturing Cost Structure Raw Material and Suppliers Manufacturing Process Industry Chain Structure

Chapter 3: Sales (Volume) and Revenue (Value) by Region (2022-2028)

Sales Revenue and market share

Chapter 4, 5 and 6: Global Single Cell Genome Sequencing Market by Type, Application & Players/Suppliers Profiles (2022-2028)

Market Share by Type & Application Growth Rate by Type & Application Drivers and Opportunities Company Basic Information

Chapter 7, 8 and 9: Single Cell Genome Sequencing Manufacturing Cost, Sourcing & Marketing Strategy Analysis

Key Raw Materials Analysis Upstream Raw Materials Sourcing Marketing Channel

Chapter 10 and 11: Single Cell Genome Sequencing Market Effect Factors Analysis and Market Size (Value and Volume) Forecast (2022-2028)

Technology Progress/Risk Sales Volume, Revenue Forecast (by Type, Application & Region)

Chapter 12, 13, 14 and 15: Single Cell Genome Sequencing Market Research Findings and Conclusion, appendix and data source

Methodology/Research Approach Data Source (Secondary Sources & Primary Sources) Market Size Estimation

Direct Buy This Premium Research Report with Flat USD 2000 Off @ https://www.coherentmarketinsights.com/promo/buynow/2059

About Coherent Market Insights

Coherent Market Insights is a global market intelligence and consulting organization that provides syndicated research reports, customized research reports, and consulting services. We are known for our actionable insights and authentic reports in various domains including aerospace and defense, agriculture, food and beverages, automotive, chemicals and materials, and virtually all domains and an exhaustive list of sub-domains under the sun. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients.

Contact Us

Mr. ShahCoherent Market Insights1001 4th Ave, #3200Seattle, WA 98154Phone: US +12067016702 / UK +4402081334027Email: [emailprotected]

More here:
Single Cell Genome Sequencing Market Will Radically Change Globally in Next Eigth Years | Illumina, Inc., Fludigim Corporation, Thermo Fisher...

Cloud Computing in Cell Biology, Genomics and Drug Development Market size was valued at USD 2.6 Billion in 20 – openPR

The global Cloud Computing in Cell Biology, Genomics and Drug Development market size was valued at USD 2.6 billion in 2021 growing at the CAGR of 24% from 2022 to 2032. Evolve Business Intelligence provides an in-dept research study that contains the ability to focus on the major market dynamics in several region across the globe. Moreover, a details assessment of the market is conducted by our analysts on various geographic including North America, Europe, Asia Pacific, Latin America, and Middle East & Africa to provide clients with opportunity to dominate the emerging markets. The Cloud Computing in Cell Biology, Genomics and Drug Development market study includes growth factors, restraining factors, challenges, and Opportunities which allows the businesses to assess the market capability of the industry. The report delivers market size from 2020 to 2032 with forecast period of 2022 to 2032. The report also contains revenue, production, sales consumption, pricing trends, and other factors which are essential for assessing any market. Request Free Sample Report or PDF Copy: https://report.evolvebi.com/index.php/sample/request?referer=openpr.com&reportCode=016017

Key Highlights:The global Cloud Computing in Cell Biology, Genomics and Drug Development market size was valued at USD 2.6 billion in 2021 growing at the CAGR of 24% from 2022 to 2032.North America dominated the market in 2021Asia Pacific is expected to grow at a highest CAGR from 2022 to 2032

Key PlayersThe Cloud Computing in Cell Biology, Genomics and Drug Development market report gives comprehensive information about the company and its past performance. The report also provides a detail market share analysis along with product benchmarking with key developments.The key players profiled in the report are:Google Inc.Oracle CorporationAmazon Web Services, Inc.BenchlingIBM Corp.Dell EmcArisglobalMicrosoft Corp.Cisco SystemsCognizant

The Global Cloud Computing in Cell Biology, Genomics and Drug Development report also includes information on company profiles, product descriptions, revenue, market share data, and contact details for several regional, global, and local companies. Due to increased technological innovation, R&D, and M&A operations in the sector, the market is becoming more popular in particular niche sectors. Additionally, a large number of regional and local vendors in the Cloud Computing in Cell Biology, Genomics and Drug Development market provide specialised product offerings according to geographical regions in keeping with the global manufacturing footprint. Due to the reliability, quality, and technological modernity of the worldwide suppliers, it is difficult for the new market entrants to compete.COVID ImpactIn terms of COVID 19 impact, the Cloud Computing in Cell Biology, Genomics and Drug Development market report also includes the following data points:COVID19 Impact on Cloud Computing in Cell Biology, Genomics and Drug Development market sizeEnd-User/Industry/Application Trend, and PreferencesGovernment Policies/Regulatory FrameworkKey Players Strategy to Tackle Negative Impact/Post-COVID StrategiesOpportunity in the Cloud Computing in Cell Biology, Genomics and Drug Development market

Get a Free Sample Copy of This Report @ https://report.evolvebi.com/index.php/sample/request?referer=openpr.com&reportCode=016017

Scope of the Report:Market Segment By Type:oPublic CloudoPrivate CloudoHybrid Cloud

Market Segment By Application:oPharmaceutical and Biotechnology CompaniesoContract Research Organizations (CROs)oClinical LaboratoriesoHospitals and Research InstitutesoOthers

For more information: https://report.evolvebi.com/index.php/sample/request?referer=openpr.com&reportCode=016017

Key Region/ Countries CoveredNorth America (US, Canada, Mexico)Europe (Germany, U.K., France, Italy, Russia, Rest of Europe)Asia-Pacific (China, India, Japan, South Korea, Rest of Asia Pacific)Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of MEA)Latin America (Mexico, Brazil, Argentina, Rest of Latin America)

Reasons to Buy this Report:Detail analysis of the impact of market drivers, restraints, and opportunitiesCompetitive Intelligence providing the understanding about the ecosystemDetails analysis of Total Addressable Market (TAM) of your productsInvestment Pockets and New Business OpportunitiesDemand-supply gap analysisStrategy Planning

Contact Us:Evolve Business IntelligenceIndiaContact: +1 773 644 5507 (US) / +441163182335 (UK)Email: sales@evolvebi.comWebsite: http://www.evolvebi.com

About EvolveBIEvolve Business Intelligence is a market research, business intelligence, and advisory firm providing innovative solutions to challenging the pain points of a business. Our market research reports include data useful to micro, small, medium, and large-scale enterprises. We provide solutions ranging from mere data collection to business advisory.Evolve Business Intelligence is built on account of technology advancement providing highly accurate data through our in-house AI-modelled data analysis and forecast tool - EvolveBI. This tool tracks real-time data including, quarter performance, annual performance, and recent developments from fortune's global 2000 companies.

This release was published on openPR.

Originally posted here:
Cloud Computing in Cell Biology, Genomics and Drug Development Market size was valued at USD 2.6 Billion in 20 - openPR

The Long and Winding Road to Eukaryotic Cells – The Scientist

This year, University of Paris-Saclay biologist Purificacin Lpez-Garca embarked with colleagues on a journey into lifes ancient past. The researchers traveled to the altiplanos of the northern Atacama Desert, high-altitude stretches of rocky soil and shrubbery in South America that are among the driest places in the world. Despite their inhospitable reputation, these plateaus may hold clues about the very origins of complex life. Amidst the dunes and barren mountains, there are pockets of lifewarm, briny pools crusted over with colorful microbial mats of cyano-bacteria and archaea stacked atop one another like crepes. Long before Earth resembled its current state, Lpez-Garca says, these microbial mats were the forests of the past, adding that scientists now use these clumps of microscopic life as analogs of past ecosystems that certainly occurred at the time when eukaryotes first appear[ed].

Each layer of these living mats is composed of different types of microbes that rely upon one another. At the surface, where light and oxygen are plentiful, photosynthesizing cyanobacteria dominate, while just below, heterotrophs that can persist in low-oxygen environments feed on their byproducts. Deeper down, the mats become dark and smelly, the result of the sulfate reducers and methanogens that populate these oxygen-bereft zones. Here, these partnerships become even more essential, with the castoffs of one group serving as fuel for another.

These close metabolic associations between organisms, a type of symbiosis known as syntrophy, may have prefaced the evolution of complex life by creating alliances that turned permanent over time, Lpez-Garca says. In this way, individuals of different microbial species could have nested within one another to create a host with one or even several symbionts. This is exactly what scientists suspect happened to form a whole new type of cell, the eukaryote, which thrived and subsequently diversified into the macroscopic array of life we see today, including humans. So-called eukaryogenesis is not defined the same way by all researchers, but broadly, the term describes an evolutionary surge toward increasing cellular complexity between 1 and 2 billion years ago.

[Eukaryogenesis is] arguably one of the most important events in the history of life, after the origin of life itself.

Daniel Mills, Ludwig-Maximilians-Universitt Mnchen

During this time, some of the defining characteristics of modern eukaryotic cellsthe nucleus, mitochondria, cytoskeleton, cell membrane, and chloroplasts, among othersmade their debut. These occurred between the first and last common ancestors of all living eukaryotes, known by their acronyms, FECA and LECA, respectively. Most of the details of these evolutionary leaps, however, remain unsettled. Researchers do not uniformly agree on which branch of life eukaryotes sprang from, which microbial players might have contributed to the process, or on the order of specific evolutionary milestones along the way. But the recent identification of the Asgard archaea, thought to be the closest living relatives to modern eukaryotes, has enlivened discussions about eukaryogenesis.

Today, at the microbial mats in the Atacama Desert and other sites throughout the world, scientists are investigating what the earliest eukaryotic cells may have looked like, the partnerships they may have struck up with other organisms, and how their molecular machinery might have functioned and evolved. Already, the discovery of the Asgards has solidified certain aspects of eukaryogenesis while raising new questions about others. I think this is the most exciting development in biology right now. So much is being discovered and so many predictions are being met, says Daniel Mills, a geobiologist and postdoctoral researcher at Ludwig-Maximilians-Universitt Mnchen who recently coauthored a paper suggesting that eukaryotes likely evolved in the absence of oxygen. Eukaryogenesis, he adds, is arguably one of the most important events in the history of life, after the origin of life itself.

Microbial mats such as these taken from the altiplanos of South Americas Atacama Desert may mimic the conditions on early Earth that gave rise to eukaryotic life.

Diversity, Ecology and Evolution of Microbes (DEEM)/Purificacin Lpez-Garca

After receiving her PhD in 2013, evolutionary microbiologist Anja Spang was shopping around for a postdoc. For her dissertation, Spang had studied a group of archaea called the Thaumarchaeota (now Nitrososphaerota), and during that work, shed picked up hints that the genomes of these and other archaea contained code for genes that produce what are known as eukaryotic signature proteins, or ESPs. These proteins should not have had recognizable counterparts in archaea, and yet, there they were. Wanting to understand just what was going on, Spang joined the lab of Thijs Ettema, an evolutionary microbiologist then at Uppsala University in Sweden, and set out in search of new data.

The team extracted genomes from sediments collected during a research cruise to a deep-sea vent site called Lokis Castle located more than 2,300 meters below the surface of the Arctic Ocean, between Greenland and Norway. Ettema told The New York Times that the initial sample amounted to less than a teaspoonful of deep-sea muck. But almost immediately, software responsible for annotating and analyzing the genetic material began to return odd resultsit flagged ESP homologs for actin, a distinctly eukaryotic protein that gives cells their shape, in a genome that was otherwise clearly archaeal. The microbes turned out to be members of a new group that Spang and the team named the Lokiarchaeota when they published their findings in Nature in 2015. In the years that followed, the team continued to flesh out this branch of the archaeal family tree, leading to the establishment of the Asgard superphylum, which in addition to Lokiarchaeota includes nods to other Norse gods, including the Thor-, Odin-, and Heimdallarchaeota.

While metagenomics have rapidly advanced the study of eukaryogenesis, the study of microfossils such as this 750-million-year-old Valeria lophostriata may also help shed light on when certain eukaryotic features first appeared.

Courtesy of Sussanah Porter

Researchers have since identified other ESPs in these groups, including homologs of proteins involved in everything from ubiquitin signaling to gamete fusion. That ESPs are so common among Asgards suggests that these microbes represent the closest living prokaryotic relatives to modern eukaryotes and that modern eukaryotes may well have inherited aspects of their molecular machinery from archaea. Indeed, most scientists now argue that an ancient Asgard or another archaeon, and not a bacterium or proto-eukaryote as many previously assumed, likely served as the first host in the evolutionary process that ultimately resulted in a new type of cell.

In 2019, researchers successfully cultured an Asgard archaeon for the first time, allowing scientists to dive deeper into their biology. Using microscopy, Hiroyuki Imachi of the Japan Agency for Marine-Earth Science and Technology and colleagues found that the cultured species, for which they proposed the name Candidatus Prometheoarchaeum syntrophicum, is small and extremely slow-growing, dividing only every two to three weeks; some microbes can double in as little as a few minutes or hours. In addition, they found that Ca. P. syntrophicumlives in close association with another archaeon called Methanogenium. Ca. P. syntrophicumgets its energy by digesting amino acids and peptides for their nitrogen, and in turn, Methanogeniumuses the hydrogen produced during that process to create its own fuel and at the same time reduce environmental hydrogen, which can induce cellular stress. This partnership confirms that Asgards engage in the type of relationships that researchers suspect gave rise to eukaryotes.

Hints of such a syntrophic relationship had been gleaned from other archaeal genomes, says Spang, who now oversees her own research group at the Royal Netherlands Institute for Sea Research, but Ca. P. syntrophicum provides tangible evidence. I was really happy when I heard of the preprint that first described the organism and its syntrophic lifestyle, she says. [It] verified that at least the metabolic predictions for the Asgards were making sense with actual experimental work.

Eukaryogenesis is broadly defined as the evolutionary path taken by increasingly complex lifeforms as they diverged from the simpler prokaryotes that dominated the early part of Earths biological history. The functional period of eukaryogenesis started just prior to the symbiosis between two prokaryotes and ended when the last common ancestor of modern eukaryotes arose. During this time, many of the most recognizable eukaryotic features appeared, including organelles such as mitochondria, nuclei, and chloroplasts, as well as cellular processes such as phagocytosis. The ordering of these events in time remains unclear.

NICOLLE FULLER, SAYO STUDIO

While the identity of original host in the symbiotic partnership that birthed modern eukaryotic cells remains mysterious, some researchers say the evidence suggests it was an archaeon rather than a bacterium. Scientists call this host, which lived more than a billion years ago, the first eukaryotic common ancestor, or FECA.

At some point in the past, the prokaryote host formed a partnership with an alphaproteobacterium and permanently engulfed it, creating the mitochondrion. Researchers debate whether phagocytosis was needed to establish this relationship, but mitochondria did help power much of eukaryotes subsequent radiation.

Numerous other features and processes associated with modern eukaryotic cells evolved during this time, including the nucleus and cytoskeleton. The order of their appearance is uncertain.

The last eukaryotic ancestor (LECA) shared by all living eukaryotes today was already a complex cell by the time eukaryotes began to radiate. Over hundreds of millions of years, LECA gave rise to the complex organisms that exist today, including fungi, protists, plants, and animals.

These early observations precipitated a flood of new research, with hundreds of papers published as preprints on bioRxiv touching on Asgards and eukaryogenesis in the last several years. The most immediate effect of the discovery of Asgards was a shift in support from a three-domain tree of life that included eukaryotes, prokaryotes, and archaea to a two-domain model, often called the eocyte hypothesis, that lumps archaea and eukaryotes together. (See illustration.)

In the three-domain model, eukaryotes belong to a separate branch that shares a common ancestor with archaea. But phylogenetic analyses suggest that complex cells emerged from within the archaea. This results in two primary domainsbacteria and archaeawith eukaryotes being nested within archaea. People were already arguing for a two-domain system before the Asgards were discovered, but then once the Asgards were described, it gave even more evidence, says Andrew Roger, a molecular biologist at Dalhousie University in Nova Scotia. He adds that the two-domain hypothesis also supports that the host during eukaryogenesis was an archaeon and not a type of proto-eukaryote that formed a distinct lineage.

People were already arguing for a two-domain system before the Asgards were discovered, but then once the Asgards were described, it gave even more evidence.

Andrew Roger, Dalhousie University

Researchers who spoke to The Scientistsay that many scientists have rallied behind the idea that the first eukaryotes evolved out of a syntrophy between an archaeal host and bacteria that somehow found their way inside to become the organelles, such as nuclei and mitochondria, that distinguish eukaryotes. The details of these relationships remain murky, but mitochondria provide the most tantalizing clues to their origin story. Theres DNA in mitochondria that we can somewhat clearly connect or trace back to alphaproteobacteria, saysLaura Eme, an evolutionary microbiologist at Frances National Centre for Scientific Research (CNRS). Even if we dont know exactly which lineage, we have a smoking gun.

There are contrasting hypotheses as to how the alphaproteobacterium would have gotten inside an archaeal host, however. In the eukaryogenesis version of the chicken-and-egg conundrum, scientists go back and forth on whether mitochondria would have been necessary to power the energetically expensive process of phagocytosis, or whether phagocytosis would have had to arise first as the means of ingesting the symbiotic partner. An oscillation between mito-early and mito-late hypotheses appears frequently in the literature, but intriguingly, there were no known examples of phagocytosis in prokaryotes until very recently, when researchers identified a phagocytosis-like process of engulfment in a bacterium. [M]any people were saying it is impossible to have the ancestor of mitochondria incorporated in any cell because phagocytosis is not known in the prokaryotic world, says Eme. Well, now we know that phagocytosis exists in bacteria, at least.

Moreover, initial observations of the Asgards point to other mechanisms of engulfment. When scientists first cultured Ca. P. syntrophicum, they immediately noticed a series of thin projections coming off of the microbesextensions of their membrane system called blebs. This observation suggested that these blebs might be able to surround an external entityperhaps with the help of those actin homologsand fuse together, trapping the foreign body inside. The phagocytosis conundrum is much less of a problem now, Eme tells The Scientist.

Researchers first identified Asgard archaea, thought to be the closest living prokaryotic relatives to modern eukaryotes, from metagenomic data in 2015. A few years later, the first Asgard was cultured, revealing unique aspects of its biology.

Hiroyuki Imachi, Masaru K. Nobu, and JAMSTEC

When it comes to the nucleus, what Lpez-Garca calls the typical diagnostic eukaryotic feature, the picture is much less clear. Hypotheses of its origin run the gamut from a bacterial endosymbiont within an amoeboid host to the remnants of a giant virus. (See From Three Domains to Two below.) In the 1990s, Lpez-Garca proposed the Syntrophy hypothesis for the origin of eukaryotes, which posited a three-party metabolic symbiosis between two bacteria and an archaeon. She maintains that this hypothesis is the only one that explains not only the origins of the nucleus, but also the so-called lipid divide, another unsettled aspect of eukaryogenesis in which the lipids that make up the cell membranes of eukaryotes are more similar to those in bacteria than to those in archaea.

A couple of years ago, Lpez-Garca and her Paris-Saclay colleague David Moreira, also affiliated with the CNRS, updated the hypothesis to reflect the discovery of Asgards, but rather than place an archaeon as the original host, they propose than an archaeonspecifically a hydrogen-producing, Asgard-like archaeonwas the original nucleus. The host, they suggest, was likely a deltaproteobacterium, and the ancestor of mitochondria an alphaproteobacterium. This idea is supported, they say, by the fact that most genes in modern eukaryotes are actually bacterial, and not archaeal, in origin, and that eukaryotic membranes are made up of phospholipids that more closely resemble bacterial ones. Our model is one potential modelit may be wrong, [or it] may be rightbut the others dont explain these discrepancies, Lpez-Garca says. And at some point, I think they should.

Michelle Leger, a postdoctoral researcher and evolutionary microbiologist at the Institute of Evolutionary Biology in Barcelona, is currently scouring the genomes of extant archaeal species to support or refute the many hypotheses floating around. With respect to the Syntrophy hypothesis, for example, if I were to imagine that there was the deltaproteobacteria in that relationship as well, I would expect a similarly clear [genomic] signal to that of the alphaproteobacteria in the mitochondrial genome, Leger tells The Scientist.She hasnt found such a signal yet, but she says she thinks the evidence does support an archaeal origin for the nucleus. Although archaeal genes make up a small fraction of the nuclear genome, the genes that play roles in highly conserved processes within the nucleus itself, such as DNA replication and transcription, are largely archaeal. So it makes sense that the nucleus developed from an archaeon, Leger says. But its not very clear what other partners might have been involved.

Even as the number of sequenced archaeal and bacterial genomes continues to increase, offering new clues about the relationship between these microbes and the rise of early eukaryotic cells, many researchers tell The Scientist its entirely possible that some questions will never be fully answered. Too much time has passed since eukaryotes first appeared on the evolutionary scene, and too much DNA has been scrambled between too many groups, for scientists to piece everything together. But that hasnt stopped them from trying.

Eme tells The Scientist that the next big frontier will be functional studies in modern eukaryotes to yield clues about how individual genes and proteins may have behaved in their early ancestors. While there was only a single Asgard genome a few years ago, today there are hundreds, and researchers are mining them for details. Now we have a clear idea of which genes in eukaryotes have been inherited from Asgard archaea, and theres a lot of novelty here, Eme says. But what we dont know, and thats really important, is what these genes did or are doing in Asgard currently.

The question of where exactly eukaryotes branch on the tree of life has been debated by scientists for decades. But the discovery of the Asgard archaeathe closest prokaryotic relatives to modern eukaryoteshas shifted most researchers away from a three-domain tree in which eukaryotes are a distinct lineage and toward a two-domain tree, in which eukaryotes emerged from within the archaea as a secondary domain.

NICOLLE FULLER, SAYO STUDIO

In 2020, researchers synthesized suspected homologs of eukaryotic actin proteins encoded in Asgard genomes. Injected into rabbit cells, these proteins bound to eukaryotic actins and performed similar functions, including aiding the flow of calcium across cell membranes. The findings suggest that a calcium-controlled actin cytoskeleton likely existed in Asgards prior to the emergence of eukaryotes. Inanother study, researchers attempted to resolve the lipid debate by expressing archaeal phospholipids in E. coli, and found that the bacteria were able to successfully incorporate as much as 30 percent of the archaeal lipids into their cell membranes. The study doesnt fully reconcile whether eukaryotes would have been able to transition their membranes from bacterial to archaeal lipidsLpez-Garca notes that bacteria with membranes composed of more than 30 percent archaeal lipids begin to diebut it does lay the groundwork for future research, Eme says.

Additional clues could come from the study of microfossils, microscopic impressions of early cells embedded in rock, says University of California, Santa Barbara, paleontologist Susannah Porter. When metagenomic sequencing came to the fore, it seemed as though fossils fell out of favor, she says, but many phylogenetic trees rely on a methodology called a molecular clock that uses fossils to anchor analyses in time. In addition, the fossils themselves can be useful, allowing scientists to determine when certain external features first appeared, adds Porter, who is currently interrogating such specimens to order certain events of early eukaryote evolution. We do have a fossil record back 2 billion to 1 billion years, but I dont think its been taken advantage of or leveraged to its full extent, she says. Maybe we could actually use these characteristics of the fossil record to be able to piece together eukaryogenesis.

Meanwhile, other researchers are devising alternate methods for timing the events of eukaryogenesis to complement that fossil evidence. For example, Berend Snel, a computational biologist at Utrecht University in the Netherlands, recently used gene duplications to correlate the lengths of branches on phylogenetic trees with timethe assumption being that the number of duplication events increases with time. That assumption was challenged by some, and even Snel admits that it may not be perfect, but breaking the story of eukaryogenesis into more manageable chunks may help resolve many of these unanswered questions, he says. What Im arguing for is that its a lot of little, small stories, but if people would integrate these small stories in the right way, there should be a tapestry that ultimately weaves a real story.

Leger agrees that our understanding of eukaryogenesis is likely to advance with baby steps. Part of the nature of these deep evolutionary questions is that we will never know, we will never have a clear proof of some of the hypotheses that were trying to develop, she says. But we can keep refining our ideas.

While much about the origin of the nucleus is speculative, one hypothesis suggests that the nucleus of modern eukaryotes may have resulted from a partnership between a prokaryotic host and a virus. This idea was first suggested in a pair of papers published back-to-back in 2001 after two researchers independently arrived at the same conclusion, and both groups recently published updates to their viral origin hypotheses following the field-rocking discovery of the Asgard archaea.

At the turn of the 21st century, Masaharu Takemura, then a molecular biologist at the Nagoya University School of Medicine in Japan, noticed that one group of viruses, the poxviruses, had DNA polymerases that were extremely similar to those found in eukaryotes, and that poxviruses replicate inside their hosts by creating self-contained compartments. Meanwhile, Philip Bell, the head of research for the biotechnology company MicroBioGen, was similarly puzzled by the differences between eukaryotes and the bacteria that led to organelles such as mitochondria. Eukaryotic chromosomes are linear, for example, while bacterial ones are circular. Many features of the nucleus just didnt support a bacterial origin.

Since that time, researchers have identified the so-called giant viruses, first described in 2003. These viruses are much larger than most, with fittingly massive genomes, and theyve since been found to harbor genes associated with various metabolic processes. Now, Takemura, Bell, and others say that a giant virus could have been the original nucleus. Giant viruses replicate within complex compartments that look very similar to modern nucleitheyre large and include both inner and outer membranesand also carry versions of genes that produce proteins involved in essential host cell processes.

The idea that the nucleus could have been a virus has been a tough sell, however. According to Purificacin Lpez-Garca, a biologist at the University of Paris-Saclay, there is no structural evidence to support it. Michelle Leger, an evolutionary microbiologist at the Institute of Evolutionary Biology in Barcelona, agrees that the hypothesis is not supported by existing data, which she argues more clearly point to an archaeon as the organism that became the eukaryotic nucleus.

But Valerie De Anda, a microbiologist at the University of Texas at Austin Marine Science Institute who studies early prokaryotic metabolism, isnt dissuaded by the current lack of evidence from the idea that a virus may well be the source of the eukaryotic nucleus. She and her colleagues are currentlylooking for mRNA-capping genes involved in transcription and translation that were suggested by Bell to have been derived from a long-ago first eukaryotic nuclear ancestor.

People dont take seriously great ideas right at the beginning . . . and then it turns out to be true, De Anda says.

Correction (October 18): This article has been updated to reflect that Valerie De Anda studies early prokaryotic metabolism, not early eukaryote metabolism, and to specify that eukaryotic signature proteins have been linked to gamete fusion, not meiosis.The Scientistregrets these errors.

See original here:
The Long and Winding Road to Eukaryotic Cells - The Scientist